Breakpoint Therapeutics GmbH (“Breakpoint”), a company dedicated to the discovery and development of drugs targeting the DNA Damage Response (DDR), announced today that it will present preclinical data from its polymerase theta (Pol θ / POLQ) inhibitor programme in an oral presentation at the DDR Inhibitors Summit, being held January 27-29, 2026 in Boston (MA), USA.
Breakpoint Therapeutics GmbH (“Breakpoint”), a company dedicated to the discovery and development of drugs targeting the DNA Damage Response (DDR), announced today that it will present preclinical data from its polymerase theta (Pol θ / POLQ) inhibitor programme in a poster at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, being held October 23-25, 2024 in Barcelona, Spain (ENA 2024).
Breakpoint Therapeutics GmbH (“Breakpoint”), a company dedicated to the discovery and development of drugs targeting the DNA Damage Response (DDR), announced today that it has nominated its first preclinical development candidate, BTX-011, an inhibitor of polymerase theta (Pol θ / POLQ) with best-in-class potential, for the treatment of solid tumours. IND-enabling activities have already commenced.
Breakpoint Therapeutics Announces Oral Presentation at the DDR Inhibitors Summit
Breakpoint Therapeutics GmbH (“Breakpoint”), a company dedicated to the discovery and development of drugs targeting the DNA Damage Response (DDR), announced today that it will present preclinical data from its polymerase theta (Pol θ / POLQ) inhibitor programme in an oral presentation at the DDR Inhibitors Summit, being held January 27-29, 2026 in Boston (MA), USA.
Breakpoint Therapeutics Announces Poster Presentation at the 36th EORTC-NCI-AACR Symposium
Breakpoint Therapeutics GmbH (“Breakpoint”), a company dedicated to the discovery and development of drugs targeting the DNA Damage Response (DDR), announced today that it will present preclinical data from its polymerase theta (Pol θ / POLQ) inhibitor programme in a poster at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, being held October 23-25, 2024 in Barcelona, Spain (ENA 2024).
Breakpoint Therapeutics Announces Development Candidate Nomination and Start of IND-Enabling Activities of Potential Best-in-Class Polymerase Theta (Pol θ / POLQ) Inhibitor
Breakpoint Therapeutics GmbH (“Breakpoint”), a company dedicated to the discovery and development of drugs targeting the DNA Damage Response (DDR), announced today that it has nominated its first preclinical development candidate, BTX-011, an inhibitor of polymerase theta (Pol θ / POLQ) with best-in-class potential, for the treatment of solid tumours. IND-enabling activities have already commenced.